UW-OncoPlex identifies genetic variants of the major cancers. Mutations are included in the test when there is an actionable therapy available—a drug that has been approved by the FDA or a therapy that is nearing approval in clinical trials.
Currently, frequent requests for an UW-OncoPlex assay come from doctors specializing in the diseases listed below.
Melanoma. UW-OncoPlex identifies three primary genes that cause variants of melanoma. Two of the available drugs are FDA approved and one has a final decision pending in 2013.
Lung Cancer. Non-small cell lung cancer has four characteristic mutations in the UW-OncoPlex panel. In some cases, the associated drugs have extended patients’ lives by 14 months—a significant improvement for patients with this disease.
Leukemia. Acute myelogenous leukemia (AML) patients are benefitting from comprehensive molecular testing from the UW-OncoPlex panel for disease prognostication to guide individualized treatment.
Sarcoma. Because there are actually more than 60 distinct types of sarcoma, doctors expect significant benefits as the UW-OncoPlex panel grows. Gastrointestinal stromal tumor has seen the most success to date. There is a strong correlation between this cancer, known as GIST, and mutations in two genes in the UW-OncoPlex panel.